303360 프로티아
기본 정보
- 섹터: KOSDAQ:제조
- 시가총액: 502억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 체외진단 · 알레르기진단 · 진단키트 · 반려동물 · 바이오칩
- 네이버 금융: 🔗
기업개요
- 동사는 2000년 설립된 체외진단 의료기기 전문기업으로, 2018년 코넥스시장 상장 후 2023년 코스닥시장에 이전상장하였음.
- 인체용 알레르기 진단키트를 주력으로 동물용 알레르기, 음식불내증, 자가면역질환 진단키트 및 항생제 감수성검사 키트를 개발·제조·판매하고 있음.
- 세계 최다 알레르기 동시 진단기술과 병렬식 라인형 바이오칩 원천기술을 기반으로 해외 80개국 90여 개 거래처를 확보하여 글로벌 시장 확대를 추진하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | 4,920 | 5,100 | 🔴 +3.66% | — | ×1.4 | 🟢 외인 | +0.6억 | +0.6 | +0.0 | +0.0 | +0.0 | -0.6 | -0.0 |
| 2026-08-06 | 5,020 | 4,920 | 🔵 -1.99% | — | ×0.2 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-08-05 | 5,020 | 5,020 | ⚪ +0.00% | — | ×0.4 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.3 | +0.2 |
| 2026-08-04 | 4,875 | 5,020 | 🔴 +2.97% | — | ×0.6 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.3 | -0.0 |
| 2026-08-03 | 4,950 | 4,875 | 🔵 -1.52% | — | ×0.5 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-31 | 4,970 | 4,950 | 🔵 -0.40% | — | ×0.3 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | -0.0 |
| 2026-07-30 | 4,810 | 4,970 | 🔴 +3.33% | — | ×1.0 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.3 | -0.0 |
| 2026-07-29 | 4,945 | 4,810 | 🔵 -2.73% | — | ×1.0 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | +0.0 |
| 2026-07-28 | 5,070 | 4,945 | 🔵 -2.47% | — | ×0.6 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-27 | 4,990 | 5,070 | 🔴 +1.60% | — | ×0.7 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | -0.0 |
| 2026-07-24 | 4,870 | 4,990 | 🔴 +2.46% | — | ×0.8 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | -0.0 | +0.0 | -0.3 | -0.0 |
| 2026-07-23 | 4,930 | 4,870 | 🔵 -1.22% | — | ×0.2 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-22 | 4,905 | 4,930 | 🔴 +0.51% | — | ×0.4 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-21 | 4,835 | 4,905 | 🔴 +1.45% | — | ×1.2 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | -0.0 |
| 2026-07-20 | 4,680 | 4,835 | 🔴 +3.31% | — | ×2.2 | 🔻 개인 | -1.0억 | -1.0 | +0.0 | +0.0 | +0.0 | +1.0 | -0.0 |
| 2026-07-16 | 4,870 | 4,680 | 🔵 -3.90% | — | ×1.2 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-15 | 3,985 | 4,870 | 🔴 +22.21% | — | ×14.4 | 🟢 외인 | +0.5억 | +0.5 | +0.0 | -0.0 | +0.0 | -0.4 | -0.1 |
| 2026-07-14 | 4,035 | 3,985 | 🔵 -1.24% | — | ×0.5 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-13 | 4,120 | 4,035 | 🔵 -2.06% | — | ×0.8 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.1 |
| 2026-07-10 | 4,055 | 4,120 | 🔴 +1.60% | — | ×0.2 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-09 | 4,040 | 4,055 | 🔴 +0.37% | — | ×0.4 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-08 | 4,120 | 4,040 | 🔵 -1.94% | — | ×1.3 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.6 | +0.2 |
| 2026-07-07 | 4,280 | 4,120 | 🔵 -3.74% | — | ×1.1 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-06 | 3,965 | 4,280 | 🔴 +7.94% | — | ×1.8 | 🟢 외인 | +0.4억 | +0.4 | +0.0 | +0.0 | +0.0 | -0.4 | -0.0 |
| 2026-07-03 | 3,915 | 3,965 | 🔴 +1.28% | — | ×0.9 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | -0.0 | +0.0 | -0.1 | -0.0 |
| 2026-07-02 | 4,030 | 3,915 | 🔵 -2.85% | — | ×0.3 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-01 | 3,900 | 4,030 | 🔴 +3.33% | — | ×0.6 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | -0.0 |
| 2026-06-30 | 3,920 | 3,900 | 🔵 -0.51% | — | ×0.3 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-06-29 | 3,795 | 3,920 | 🔴 +3.29% | — | ×0.7 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.3 | -0.0 |
| 2026-06-26 | 3,875 | 3,795 | 🔵 -2.06% | — | ×1.9 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-06-25 | 3,930 | 3,875 | 🔵 -1.40% | — | ×1.1 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
일자별 사유 (최신 위)
2026-07-15
- 사유: —
- 섹터 컨텍스트: KOSDAQ:제조 (smart +1,144억)
- 매크로 원인: HLB 리보세라닙 FDA 제조 리스크 해소 기대에 그룹주 무더기 상한가, 미프진 허가 검토·항암신약 모멘텀 가세 (보통)